Next Article in Journal
DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome
Next Article in Special Issue
The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective
Previous Article in Journal
Vitamin A Rich Diet Diminishes Early Urothelial Carcinogenesis by Altering Retinoic Acid Signaling
Previous Article in Special Issue
Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer Can Reduce the Risk of Death in Obese Women: The EMILI Study
Open AccessReview

Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease

Cellular & Molecular Metabolism Laboratory, Monash Institute of Pharmacological Sciences, Monash University, Parkville, VIC 3052, Australia
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1714; https://doi.org/10.3390/cancers12071714
Received: 11 May 2020 / Revised: 24 June 2020 / Accepted: 25 June 2020 / Published: 28 June 2020
(This article belongs to the Special Issue How Does Obesity Cause Cancer?)
Obesity is recognised as a risk factor for many types of cancers, in particular hepatocellular carcinoma (HCC). A critical factor in the development of HCC from non-alcoholic fatty liver disease (NAFLD) is the presence of non-alcoholic steatohepatitis (NASH). Therapies aimed at NASH to reduce the risk of HCC are sparse and largely unsuccessful. Lifestyle modifications such as diet and regular exercise have poor adherence. Moreover, current pharmacological treatments such as pioglitazone and vitamin E have limited effects on fibrosis, a key risk factor in HCC progression. As NAFLD is becoming more prevalent in developed countries due to rising rates of obesity, a need for directed treatment is imperative. Numerous novel therapies including PPAR agonists, anti-fibrotic therapies and agents targeting inflammation, oxidative stress and the gut-liver axis are currently in development, with the aim of targeting key processes in the progression of NASH and HCC. Here, we critically evaluate literature on the aetiology of NAFLD-related HCC, and explore the potential treatment options for NASH and HCC. View Full-Text
Keywords: NAFLD; NASH; hepatocellular carcinoma; treatments NAFLD; NASH; hepatocellular carcinoma; treatments
Show Figures

Figure 1

MDPI and ACS Style

Smeuninx, B.; Boslem, E.; Febbraio, M.A. Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease. Cancers 2020, 12, 1714.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop